PubMed Health⌕ Search

Biomedical subjects

D Frye

Publications and source records attributed to D Frye.

43 records · Page 3Linked to original sources
PubMed1986

Initial clinical studies with copovithane.

Copovithane is a new copolymer of low molecular weight and with a significant in vivo antitumor activity in preclinical trials. The mechanism of action is unknown. Ninety-one patients with various metastatic neoplasms beyond the curable stage were treated with copovithane by weekly intravenous administration. Dose levels ranged from 1 to 33 g/m2/week. No dose-limiting toxicity was reached. Tolerance was excellent, with minor fatigue, occasional nausea, and intermittent proteinuria as the only significant side effects in less than 25% of patients. Two patients achieved a partial remission, and five patients reached minor responses during therapy. Antitumor effects were noted only in cutaneous and subcutaneous metastases. Extensive immunologic evaluation revealed some improvement in helper:suppressor T cell ratio, in vitro cytotoxicity tests, and lymphocyte blastogenic responses in patients treated at intermediate levels. The immunologic testing also suggested that the higher dose levels (22-33 g/m2 weekly) might adversely affect the immune response. The clinical relevance of these changes is uncertain. Phase II clinical trials are recommended utilizing weekly doses between 10 and 15 g/m2.

Adult↗
PubMed1985

Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.

Thirty-nine evaluable, postmenopausal patients with metastatic breast carcinoma were treated with medroxyprogesterone acetate administered orally at daily doses of 800 mg/day in 29 patients and 400 mg/day in 10 patients. One patient experienced a complete remission and 16 had partial remissions for an objective remission rate of 44%. There was no apparent difference in response between the two dose levels. Median remission duration was 8 months, and median survival for the whole group is expected to exceed 18 months. Increased appetite (66%) and weight gain (97%) were the most common side effects, followed by fluid retention, muscle cramps, and increased blood pressure. Performance status improved and white blood cell and platelet counts increased in the majority of patients. Medroxyprogesterone acetate is an effective hormonal agent in the treatment of metastatic breast cancer.

Administration, Oral↗
PubMedDate not supplied

Continuous electroencephalographic monitoring during carotid endarterectomy.

Four hundred and twenty-seven carotid endarteriectomies were performed on 377 patients. The electroencephalogram was used as the sole determinant for the use of a carotid shunt in 386 carotid endarterectomies. With clamping of the internal carotid artery, 51 (13%) had electroencephalographic changes. The most common electroencephalographic change (60%) was rapid, ipsilateral attenuation of background activity. In the 30 day follow up period there were 3 deaths (0.7%) and 11 strokes (2.5%). Two patients (0.5%) had intraoperative strokes. The combined morbidity and mortality was 2.8% (12 of 427). Neurologic complications increased significantly with contralateral carotid occlusion. The electroencephalogram correlated well with neurological deficits occurring in surgery, but stump pressures neither correlated with neurological deficits nor electroencephalographic changes. Continuous electroencephalographic monitoring during carotid endarterectomy is an effective method of determining significant cerebral ischemia and the need for a carotid shunt.

Adult↗